Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Related Articles


Optimizing GDMT for HFrEF During Hospitalization

Neal M Dixit, Shivani Shah, Boback Ziaeian,


Citation: US Cardiology Review 2021;15:e07.

Treating Mitral Regurgitation in the Wake of COAPT

Kelly H Schlendorf, Jared O’Leary, JoAnn Lindenfeld,


Citation: US Cardiology Review 2020;14:e06.

COVID-19 Pandemic and Cardiovascular Disease

Aniket S Rali, Andrew J Sauer,


Citation: US Cardiology Review 2020;14:e01.

Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure

Deepak Bhatt, Anna Meta Dyrvig Kristensen, Manan Pareek,


Citation: US Cardiology Review 2019;13(2):83–7.